ArticleCureus2026
Exploratory Clinical and Cost Evaluation of Robot-Assisted Adrenalectomy Using the hinotori™ Surgical Robotic System: A Single-Center Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough the hinotori™ surgical robotic system is Japan's first domestically developed platform, evidence regarding its clinical feasibility remains limited. Because adrenalectomy is a standardized minimally invasive procedure with well-defined perioperative outcomes, it provides an appropriate model for evaluating newly introduced robotic platforms. We evaluated the clinical outcomes and medical costs of robot-assisted adrenalectomy (RAAD) using the hinotori™ system (H-RAAD) and compared them retrospectively with those of da Vinci Xi™-assisted RAAD (D-RAAD). MATERIALS AND
methodsWe retrospectively examined patients who underwent RAAD at Nippon Medical School Hospital between September 2023 and May 2025. Baseline demographic characteristics, perioperative variables, postoperative outcomes, pathological findings, and medical costs extracted from the Diagnosis Procedure Combination (DPC) database were evaluated.
resultsWe evaluated 12 patients (H-RAAD, n = 5; D-RAAD, n = 7). Baseline characteristics were comparable between the groups, although the median tumor diameter was numerically smaller in the H-RAAD group. The median anesthesia, operative, and console times in the H-RAAD group were 264 (253-307, U = 10.0, p = 0.22), 189 (156-264, U = 10.0, p = 0.29), and 108 (71-180, U = 14.0, p = 0.57) minutes, respectively, comparable with those in the D-RAAD group. Total medical costs per case were similar between the D-RAAD ($6,333.1) and H-RAAD ($6,398.4) groups (U = 23.0, p = 0.34).
conclusionsIn this small cohort, H-RAAD was completed safely without conversion or major complications, demonstrating perioperative outcomes similar to those of D-RAAD. Although individual cost components varied, total reimbursed medical costs under the DPC system were comparable. Given the limited sample size and exclusion of robotic system capital and maintenance costs, these findings remain exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.